Company to Initiate a Review of Strategic Opportunities to Enhance Shareholder Value in Fiscal Q2
Fiscal Year 2023 Product Revenue up 21% Year-Over-Year
Company to Host Webcast Today at
Fiscal 2023 and Fourth Quarter and Recent Highlights
Corporate Updates
Key Business Highlights
High Power Segment Update –
Low Power Segment Update –
“We continue to see strong fundamental growth trends driven primarily by increased design wins for both the high-power and low-power market segments. We believe these trends point to the Company resuming sequential product revenue growth beginning in the second quarter of fiscal 2024,” commented Transphorm’s President, CEO and Co-Founder,
“We believe the past quarter and fiscal year have been extremely important toward positioning us strategically for future growth. We expect our recently announced rights offering and the asset-based debt financing initiatives we are pursuing will significantly improve our cash position and put us in a strong position to pursue the increased opportunity funnel and allow us to focus on product innovation, operational capabilities and collaborative opportunities,” stated
1 Cascode GaN improves efficiency – A teardown of Razer 280W Power Adapter -
Fiscal 2023 Fourth Quarter Financial Results
Revenue for the fourth quarter of fiscal 2023 was
Operating expenses on a GAAP basis were
GAAP net loss for the fourth quarter of fiscal 2023 was
Fiscal 2023 Full Year Financial Results
Revenue for the fiscal 2023 was
Operating expenses on a GAAP basis were
GAAP net loss for fiscal 2023 was
Cash, cash equivalents and restricted cash as of
Fiscal 2024 First Quarter Guidance
For the first quarter of fiscal 2024, the Company expects:
The Company currently forecasts it will have cash runway into the second half of
Conference Call and Webcast Information
Event: |
Transphorm Fiscal 2023 Fourth Quarter and Full Year Financial Results |
Date: |
|
Time: |
|
Registration: |
https://register.vevent.com/register/BIff2d46a2f63c464b80cc25344b9c6e09 |
Investors and analysts may also join the webcast on the Events section on the Company’s website.
A replay and the supporting presentation materials will be available on the day of the conference call and for approximately 90 days on the Investor Relations section of the Company’s website.
About
Non-GAAP Financial Measures
This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.
A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company’s expectations related to its planned rights offering and the asset-based debt financing initiatives it is pursuing, including the potential proceeds from such efforts; the Company’s current expectation regarding its cash runway, without any additional financing; the expected date through which proceeds from the rights offering and any debt financing, if consummated, would fund the Company’s operations; the expectation that the rights offering and debt financing initiatives will allow the Company to increase its focus on product innovation, operational capabilities and collaborative opportunities; expected key stockholder participation in the rights offering; the Company’s intent to conduct a strategic review in the second quarter of fiscal 2024; the Company’s 5-year pipeline and anticipated future growth; the Company’s expectation that sequential product revenue growth will resume in the second quarter of fiscal 2024; the Company’s targeted ramp in the microinverter segment; the Company’s expectations for future products, design-ins and market acceptance; the Company’s guidance for the first quarter of fiscal 2024; and the information set forth in the quotes by the Company’s management set forth herein. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: prevailing market conditions; the Company’s ability to commence and successfully complete the rights offering as expected; whether the Company’s stockholders of record (including those that have indicated interest in participating in the rights offering) will exercise their rights to purchase common stock and the amount subscribed; whether the Company will be able to successfully close any debt financing; that any funds raised through the rights offering or any debt financing may not fund the Company’s working capital requirements for as long as anticipated; that the Company’s current forecasted cash runway, without any additional financing, may not last as long as anticipated; that the Company’s anticipated strategic review may not result in any transaction (or that the terms of such transaction may not be favorable or acceptable to the Company or its stockholders); risks related to Transphorm’s operations, such as additional financing requirements, access to capital and market acceptance of its current and future products; competition; the ability of
Condensed Consolidated Balance Sheets (in thousands) |
|||||||
|
|
|
|
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
15,527 |
|
|
$ |
33,435 |
|
Restricted cash |
|
500 |
|
|
|
500 |
|
Accounts receivable |
|
4,396 |
|
|
|
2,558 |
|
Inventory |
|
8,406 |
|
|
|
6,330 |
|
Prepaid expenses and other current assets |
|
1,859 |
|
|
|
1,971 |
|
Total current assets |
|
30,688 |
|
|
|
44,794 |
|
Property and equipment, net |
|
7,890 |
|
|
|
1,649 |
|
Operating lease right-of-use assets |
|
3,033 |
|
|
|
— |
|
|
|
1,079 |
|
|
|
1,180 |
|
Intangible assets, net |
|
321 |
|
|
|
617 |
|
Investment in joint venture |
|
715 |
|
|
|
143 |
|
Other assets |
|
726 |
|
|
|
263 |
|
Total assets |
$ |
44,452 |
|
|
$ |
48,646 |
|
|
|
|
|
||||
Liabilities and stockholders’ equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable and accrued expenses |
$ |
7,895 |
|
|
$ |
3,588 |
|
Deferred revenue |
|
— |
|
|
|
346 |
|
Accrued interest |
|
180 |
|
|
|
180 |
|
Accrued payroll and benefits |
|
1,458 |
|
|
|
1,171 |
|
Operating lease liabilities |
|
404 |
|
|
|
— |
|
Revolving credit facility |
|
12,000 |
|
|
|
— |
|
Total current liabilities |
|
21,937 |
|
|
|
5,285 |
|
Revolving credit facility, net of current portion |
|
— |
|
|
|
12,000 |
|
Operating lease liabilities, net of current portion |
|
2,670 |
|
|
|
— |
|
Other liabilities |
|
230 |
|
|
|
— |
|
Total liabilities |
|
24,837 |
|
|
|
17,285 |
|
Commitments and contingencies |
|
|
|
||||
Stockholders’ equity: |
|
|
|
||||
Common stock |
|
6 |
|
|
|
5 |
|
Additional paid-in capital |
|
230,272 |
|
|
|
211,190 |
|
Accumulated deficit |
|
(209,236 |
) |
|
|
(178,638 |
) |
Accumulated other comprehensive loss |
|
(1,427 |
) |
|
|
(1,196 |
) |
Total Stockholders’ equity |
|
19,615 |
|
|
|
31,361 |
|
Total liabilities and stockholders’ equity |
$ |
44,452 |
|
|
$ |
48,646 |
|
Condensed Consolidated Statements of Operations (unaudited) (in thousands except share and per share data) |
|||||||||||||||||||
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Revenue, net |
$ |
3,192 |
|
|
$ |
4,493 |
|
|
$ |
4,927 |
|
|
$ |
16,511 |
|
|
$ |
24,050 |
|
Cost of goods sold |
|
3,017 |
|
|
|
7,162 |
|
|
|
3,789 |
|
|
|
17,461 |
|
|
|
12,530 |
|
Gross (loss) profit |
|
175 |
|
|
|
(2,669 |
) |
|
|
1,138 |
|
|
|
(950 |
) |
|
|
11,520 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||||
Research and development |
|
3,013 |
|
|
|
2,325 |
|
|
|
1,632 |
|
|
|
8,908 |
|
|
|
6,655 |
|
Sales and marketing |
|
1,651 |
|
|
|
1,447 |
|
|
|
1,047 |
|
|
|
5,247 |
|
|
|
3,535 |
|
General and administrative |
|
3,854 |
|
|
|
3,457 |
|
|
|
2,917 |
|
|
|
13,672 |
|
|
|
11,226 |
|
Total operating expenses |
|
8,518 |
|
|
|
7,229 |
|
|
|
5,596 |
|
|
|
27,827 |
|
|
|
21,416 |
|
Loss from operations |
|
(8,343 |
) |
|
|
(9,898 |
) |
|
|
(4,458 |
) |
|
|
(28,777 |
) |
|
|
(9,896 |
) |
Interest expense |
|
180 |
|
|
|
184 |
|
|
|
181 |
|
|
|
730 |
|
|
|
792 |
|
Loss in joint venture |
|
659 |
|
|
|
799 |
|
|
|
677 |
|
|
|
2,724 |
|
|
|
3,971 |
|
Changes in fair value of promissory note |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(605 |
) |
Other income, net |
|
(392 |
) |
|
|
(421 |
) |
|
|
(317 |
) |
|
|
(1,633 |
) |
|
|
(3,819 |
) |
Loss before tax expense |
|
(8,790 |
) |
|
|
(10,460 |
) |
|
|
(4,999 |
) |
|
|
(30,598 |
) |
|
|
(10,235 |
) |
Tax expense |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net loss |
$ |
(8,790 |
) |
|
$ |
(10,460 |
) |
|
$ |
(4,999 |
) |
|
$ |
(30,598 |
) |
|
$ |
(10,235 |
) |
Net loss per share - basic and diluted |
$ |
(0.15 |
) |
|
$ |
(0.18 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.54 |
) |
|
$ |
(0.22 |
) |
Weighted average common shares outstanding - basic and diluted |
|
57,144,218 |
|
|
|
56,739,450 |
|
|
|
53,343,862 |
|
|
|
56,227,007 |
|
|
|
46,056,331 |
|
Reconciliation of GAAP and Non-GAAP Financial Information (unaudited) (in thousands except per share data) |
||||||||||||||||||||
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
GAAP net loss |
$ |
(8,790 |
) |
|
$ |
(10,460 |
) |
|
$ |
(4,999 |
) |
|
$ |
(30,598 |
) |
|
$ |
(10,235 |
) |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
||||||||||
Stock-based compensation |
|
858 |
|
|
|
1,123 |
|
|
|
758 |
|
|
|
3,199 |
|
|
|
2,614 |
|
|
Depreciation |
|
174 |
|
|
|
180 |
|
|
|
147 |
|
|
|
672 |
|
|
|
547 |
|
|
Amortization |
|
74 |
|
|
|
74 |
|
|
|
74 |
|
|
|
296 |
|
|
|
296 |
|
|
Total other expense, net |
|
447 |
|
|
|
562 |
|
|
|
541 |
|
|
|
1,821 |
|
|
|
339 |
|
|
Total adjustments to GAAP net loss |
|
1,553 |
|
|
|
1,939 |
|
|
|
1,520 |
|
|
|
5,988 |
|
|
|
3,796 |
|
|
Non-GAAP net loss |
$ |
(7,237 |
) |
|
$ |
(8,521 |
) |
|
$ |
(3,479 |
) |
|
$ |
(24,610 |
) |
|
$ |
(6,439 |
) |
|
GAAP net loss per share - basic and diluted |
$ |
(0.15 |
) |
|
$ |
(0.18 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.54 |
) |
|
$ |
(0.22 |
) |
|
Adjustment |
|
0.02 |
|
|
|
0.03 |
|
|
|
0.02 |
|
|
|
0.10 |
|
|
|
0.08 |
|
|
Non-GAAP net loss per share - basic and diluted |
$ |
(0.13 |
) |
|
$ |
(0.15 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.44 |
) |
|
$ |
(0.14 |
) |
|
Weighted average common shares outstanding - basic and diluted |
|
57,144,218 |
|
|
|
56,739,450 |
|
|
|
53,343,862 |
|
|
|
56,227,007 |
|
|
|
46,056,331 |
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|||||
GAAP operating expenses |
$ |
8,518 |
|
$ |
7,229 |
|
$ |
5,596 |
|
$ |
27,827 |
|
$ |
21,416 |
Adjustments: |
|
|
|
|
|
|
|
|
|
|||||
Stock-based compensation |
|
796 |
|
|
1,035 |
|
|
715 |
|
|
2,955 |
|
|
2,453 |
Depreciation |
|
101 |
|
|
102 |
|
|
94 |
|
|
394 |
|
|
385 |
Amortization |
|
74 |
|
|
74 |
|
|
74 |
|
|
296 |
|
|
296 |
Total adjustments to GAAP operating expenses |
|
971 |
|
|
1,211 |
|
|
883 |
|
|
3,645 |
|
|
3,134 |
Non-GAAP operating expenses |
$ |
7,547 |
|
$ |
6,018 |
|
$ |
4,713 |
|
$ |
24,182 |
|
$ |
18,282 |
Condensed Consolidated Statements of Cash Flows (unaudited), (in thousands) |
|||||||
|
|
||||||
|
Twelve Months Ended |
||||||
|
2023 |
|
2022 |
||||
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(30,598 |
) |
|
$ |
(10,235 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Provision for inventory |
|
3,127 |
|
|
|
196 |
|
Depreciation and amortization |
|
968 |
|
|
|
843 |
|
Amortization of right-of-use assets |
|
566 |
|
|
|
— |
|
Perpetual licensing revenue from a related party |
|
— |
|
|
|
(8,000 |
) |
Stock-based compensation |
|
3,199 |
|
|
|
2,614 |
|
Interest cost |
|
— |
|
|
|
107 |
|
Gain on promissory note conversion |
|
— |
|
|
|
(1,222 |
) |
Gain on sale of equipment |
|
(106 |
) |
|
|
— |
|
Loss in joint venture |
|
2,724 |
|
|
|
2,516 |
|
Changes in fair value of derivative instruments |
|
(14 |
) |
|
|
— |
|
Changes in fair value of promissory note |
|
— |
|
|
|
(605 |
) |
Changes in operating assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
(1,838 |
) |
|
|
(940 |
) |
Inventory |
|
(5,203 |
) |
|
|
(4,303 |
) |
Prepaid expenses and other current assets |
|
125 |
|
|
|
(518 |
) |
Other assets |
|
(463 |
) |
|
|
11 |
|
Accounts payable, accrued expenses, and other liabilities |
|
1,586 |
|
|
|
198 |
|
Deferred revenue |
|
(346 |
) |
|
|
(159 |
) |
Accrued payroll and benefits |
|
288 |
|
|
|
(239 |
) |
Operating lease liabilities |
|
(524 |
) |
|
|
— |
|
Net cash used in operating activities |
|
(26,509 |
) |
|
|
(19,736 |
) |
Cash flows from investing activities: |
|
|
|
||||
Purchases of property and equipment |
|
(6,936 |
) |
|
|
(595 |
) |
Proceeds from sale of equipment |
|
111 |
|
|
|
— |
|
Investment in joint venture |
|
(3,321 |
) |
|
|
(4,526 |
) |
Net cash used in investing activities |
|
(10,146 |
) |
|
|
(5,121 |
) |
Cash flows from financing activities: |
|
|
|
||||
Proceeds from stock option exercise |
|
710 |
|
|
|
221 |
|
Proceeds from issuance of common stock |
|
16,000 |
|
|
|
50,900 |
|
Cost associated with issuance of common stock |
|
(280 |
) |
|
|
(1,127 |
) |
Payment for taxes related to net share settlement of restricted stock units |
|
(546 |
) |
|
|
(768 |
) |
Proceeds from exercise of warrants |
|
2,950 |
|
|
|
272 |
|
Net cash provided by financing activities |
|
18,834 |
|
|
|
49,498 |
|
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash |
|
(87 |
) |
|
|
(206 |
) |
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
(17,908 |
) |
|
|
24,435 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
33,935 |
|
|
|
9,500 |
|
Cash, cash equivalents and restricted cash at end of period |
$ |
16,027 |
|
|
$ |
33,935 |
|
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |
|
|
|
||||
Cash and cash equivalents |
$ |
15,527 |
|
|
$ |
33,435 |
|
Restricted cash |
|
500 |
|
|
|
500 |
|
Cash, cash equivalents and restricted cash at end of period |
$ |
16,027 |
|
|
$ |
33,935 |
|
|
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230627964440/en/
Investor Contacts:
transphorm@kcsa.com
Company Contact:
Chief Financial Officer
1-805-456-1300 ext. 140
cmcaulay@transphormusa.com
Source: